114 related articles for article (PubMed ID: 16951521)
1. [Effects of rosiglitazone on endothelium-dependent vasodilation in patients with Type 2 diabetes].
Wu J; Lei MX; Liu L; Huang YJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 31(4):570-4. PubMed ID: 16951521
[TBL] [Abstract][Full Text] [Related]
2. [Effects of rosiglitazone on serum leptin and insulin resistance in patients with Type 2 diabetes].
Wu J; Lei MX; Chen HL; Sun ZX
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):623-6. PubMed ID: 16114542
[TBL] [Abstract][Full Text] [Related]
3. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
4. [Changes of endothelium-dependent vasodilation in patients with impaired glucose tolerance and type 2 diabetes].
Wu J; Lei MX; Liu L; Huang YJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):609-14. PubMed ID: 17767051
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
Sahin M; Tutuncu NB; Ertugrul D; Tanaci N; Guvener ND
J Diabetes Complications; 2007; 21(2):118-23. PubMed ID: 17331860
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Ferrari I; Gravina A; Fogari R
Hypertens Res; 2006 Nov; 29(11):849-56. PubMed ID: 17345784
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic polymorphisms of leptin and TNF-alpha on rosiglitazone response in Chinese patients with type 2 diabetes.
Liu HL; Lin YG; Wu J; Sun H; Gong ZC; Hu PC; Yin JY; Zhang W; Wang D; Zhou HH; Liu ZQ
Eur J Clin Pharmacol; 2008 Jul; 64(7):663-71. PubMed ID: 18438653
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
12. [Relations between serum adipocyte fatty acid-binding protein and type 2 diabetes in a community population].
YE WH; PENG XH; AI YQ; CHEN H; ZHANG H; CAI DH
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):508-11. PubMed ID: 21421494
[TBL] [Abstract][Full Text] [Related]
13. [The effect of single nucleotide polymorphism SNP + 45 of the adiponectin gene on the rosiglitazone maleate response in patients with type 2 diabetes].
Zhang H; Jia WP; Hu C; Zhang R; Wang CR; Bao YQ; Lu JX; Xu J; Xiang KS
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(34):2390-3. PubMed ID: 18036314
[TBL] [Abstract][Full Text] [Related]
14. Impact of retinol binding protein 4 polymorphism on rosiglitazone response in Chinese type 2 diabetic patients.
Zhou F; Huang Q; Dai X; Yin J; Wu J; Zhou H; Gong Z; Liu Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 36(10):949-57. PubMed ID: 22086013
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
16. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
Yu X; Chen P; Wang H; Zhu T
Med Princ Pract; 2013; 22(2):156-60. PubMed ID: 22964975
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.
Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D
In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765
[TBL] [Abstract][Full Text] [Related]
19. The influence of homocysteine levels on endothelial function and their relation with microvascular complications in T2DM patients without macrovascular disease.
Karabag T; Kaya A; Temizhan A; Koç F; Yavuz S; Cam S
Acta Diabetol; 2007 Jun; 44(2):69-75. PubMed ID: 17530470
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
